{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031335","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.730680+00:00","generated_at":"2026-06-21T23:10:41.475407+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Co-Diagnostics Q3 revenue $5.1M (down 83% YoY); net loss $1.4M vs prior-year income $11.5M","bullets":["Revenue $5.1M, down from $30.1M a year ago; operating loss $6.5M vs income $13.6M.","Net loss $1.4M ($0.04 loss per diluted share) vs net income $11.5M in Q3 2021.","Adjusted EBITDA loss $4.1M; cash, equivalents, and marketable securities $86.5M.","Repurchased 2.9M shares at avg $3.61; generated $1.1M operating cash flow in Q3.","Co-Dx PCR Home platform nearing clinical evaluations; shipped Monkeypox test and appointed new CSO Dr. Mark Poritz."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031335","json":"https://secwatch.observer/filing/0001493152-22-031335.json","markdown":"https://secwatch.observer/filing/0001493152-22-031335.md","text":"https://secwatch.observer/filing/0001493152-22-031335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/0001493152-22-031335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:10:41.475407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5165c7f7b3dc6a5839e9134b9a20612943173242","claim":"Co-Diagnostics, Inc. reported the third quarter ended September 30, 2022 results: revenue Revenue of $5.1 million, net income Net loss of $1.4 million, EPS loss of $0.04 per fully diluted share.","evidence_excerpt":"development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results: ● Revenue of $5.1 million, down from $30.1 million during the prior year period, but an increase of 1.4% from the current year second quarter ● Gross profit of $4.3 million, representing 84.9% of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/0001493152-22-031335-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"Revenue of $5.1 million"},{"label":"Net income","value":"Net loss of $1.4 million"},{"label":"EPS","value":"loss of $0.04 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}